摘要 |
The present invention relates to an antibody targeting VEGFR-2, and more particularly a dual-target antibody of novel form in which calcium-binding EGF-like domains 11 and 12 of human Notch1 are bound to the N-terminal of the Tanibirumab light chain, a gene coding for same, a recombinant expression vector comprising the gene, host cells that have been genetically modified by using the recombinant expression vector and a method of producing a dual-target antibody by culturing the host cells, a pharmaceutical composition comprising the dual-target antibody, and a method for measuring the DLL4 antagonist efficacy of the dual-target antibody wherein Notch 1 activity is measured by the co-culturing of human umbilical endothelial cells (HUVEC) and a cell strain expressing human DLL4(hDLL4). The dual-target antibody according to the present invention has the advantages that, by more effectively simultaneously disrupting signal transmission following two different pathways of VEGF/VEGFR-2 and DLL4/Notch1, it is possible to treat various diseases associated with vasculogenesis such as tumours and, more particularly, possible to overcome the resistance that occurs following the use of a neovascular therapeutic agent alone, and that, by directly targeting cancer stem cells, it is possible to fundamentally prevent the recurrence of cancer. |
申请人 |
PHARMABCINE INC. |
发明人 |
KIM, JOONG KYU;YOO, JIN SAN;LEE, SANG HOON;LEE, WEON SUP;KIM, SUNG WOO;SHIM, SANG RYEOL;YOO, JIN SANG;LEE, YOUNG AE;EMPTY;BYUN, SANG SOON;LEE, HYUK JOON;KIM, DO YUN;KIM, YEUN JU;CHOI, JIN HEE;NAHM, KYUNG HEE;NAM, JU RYUNG;JEONG, JONG GEUN;JEONG, BO YOUNG;LEE, EUN JIN;LEE, SEON YOUNG;PARK, IN SOOK;LEE, JIN SOOK;YOON, JAE BONG;KIM, NAM YE;OH, SEON HWAN |